IPO - Cellectar Biosciences, Inc.

Form Type: 424B4

Filing Date: 2025-07-02

Corporate Action: Ipo

Type: New

Accession Number: 000110465925064897

Filing Summary: Cellectar Biosciences, Inc. filed a prospectus for the offering of 865,000 Class A Units and 335,000 Class B Units, comprising shares of common stock and warrants. Each Class A Unit is priced at $5.00, while Class B Units are priced at $4.99999. The securities, designed for a late-stage clinical biopharmaceutical company focused on cancer treatment, include common stock and common warrants, with exercises available for the warrants under specified terms. The Class A and Class B Units will not be certificated, and the company will not change the authorized shares or par value post-offering. The underwriter has an option for an additional 180,000 shares to cover over-allotments. Recent developments include a reverse stock split of one-for-thirty and FDA designations for the company’s drug candidates. Executives of the company are committing to purchase 25,000 Class A Units in this offering, affirming confidence in the offering. The expected delivery of securities is set for July 2, 2025, with proceeds anticipated to advance clinical studies related to the company’s proprietary drug platform.

Form Type: S-1/A

Filing Date: 2025-06-30

Corporate Action: Ipo

Type: New

Accession Number: 000110465925063849

Filing Summary: Cellectar Biosciences, Inc. is filing an amendment to its registration statement under the Securities Act for a proposed public offering of its securities, specifically up to 755,667 Class A Units and Class B Units consisting of common stock and warrants. The offering aims to raise capital to support their development of phospholipid ether drug conjugate-based cancer therapies. The company is also in the process of exploring various strategic alternatives to advance its drug development pipeline, including possible mergers and acquisitions. The BIO is focused on pioneering treatments that target cancer cells while minimizing off-target effects. A significant aspect of the filing is the recently executed reverse stock split at a ratio of 1:30, which the company believes enhances its market position. There should be a strong interest in the Class A and B Units, reflecting the company's push toward enhanced capital structure and long-term growth strategy. The estimated price for Class A Units is mentioned as $7.94, based on recent market activity. They will commence offering the securities once the registration becomes effective, aiming to capitalize on the favorable conditions within the biopharma market to facilitate future growth in cancer treatment products.

Form Type: S-1

Filing Date: 2025-06-26

Corporate Action: Ipo

Type: New

Accession Number: 000110465925062834

Filing Summary: Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company dedicated to developing cancer therapies using its proprietary phospholipid ether drug conjugate delivery platform. They are conducting an initial public offering (IPO) of securities including Class A Units composed of shares of common stock and warrants, as well as Class B Units consisting of pre-funded warrants and common warrants. The registration statement outlines potential risks associated with investment, details on securities, the offering process, and strategic pursuits including exploring mergers and partnerships to advance their drug pipeline. The company is focused on radioconjugate programs, highlighted by FDA Breakthrough Therapy Designation for iopofosine I 131 in treating relapsed/refractory Waldenstrom macroglobulinemia. The release provides an overview of upcoming clinical trials for CLR 125 and CLR 225, aiming to initiate Phase 1 studies within the year. The funds from this offering are intended to cover operational expenses and support clinical trials.

Form Type: DRS

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052508

Filing Summary: Cellectar Biosciences, Inc. filed a preliminary prospectus for an IPO to register securities under the Securities Act of 1933. The offering includes up to Class A and Class B Units, with each Class A Unit consisting of one share of common stock and one common warrant, while Class B Units consist of a pre-funded warrant and a common warrant. The filing is part of an ongoing effort to advance their drug development pipeline focused on cancer therapies, utilizing a proprietary phospholipid ether drug conjugate platform. The company announced strategic alternatives to enhance development, potentially including partnerships or mergers. The planned clinical trials and drug programs highlight their commitment to leveraging their PDC technology for targeted cancer treatment, with several ongoing and upcoming studies for drugs like CLR 125 and iopofosine. The registration statement aims to provide necessary resources for operating expenses and clinical studies.

Form Type: CORRESP

Filing Date: 2025-02-04

Corporate Action: Ipo

Type: New

Accession Number: 000110465925009108

Filing Summary: Cellectar Biosciences, Inc. has requested the Securities and Exchange Commission to accelerate the effective date of its Registration Statement on Form S-1 (Registration No. 333-284580) filed on January 29, 2025. The company aims for the registration to become effective at 5:00 p.m. on February 6, 2025, or as soon as practicable thereafter. This request indicates the company's intention to proceed with an initial public offering (IPO). The company expresses appreciation for the staff's cooperation and provides contact information for any questions or comments.

Form Type: S-1

Filing Date: 2025-01-29

Corporate Action: Ipo

Type: New

Accession Number: 000141057825000060

Filing Summary: Cellectar Biosciences, Inc. filed a Form S-1 registration statement with the SEC on January 29, 2025. This registration statement relates to the proposed initial public offering (IPO) of shares of common stock. The company aims to raise capital for funding its ongoing research and development activities, expanding its operational capabilities, and for general corporate purposes. The S-1 includes detailed information regarding the company's business model, financial statements, risk factors, management structure, and use of proceeds from the offering. The document outlines the terms of the offering, including the number of shares to be offered and anticipated pricing, which will be finalized during the marketing period prior to the IPO.